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Extracellular vesicles (EVs), including endosome-derived nanovesicles (exosomes), are 
involved in cell–cell communication. Through transfer of their molecular contents, extra-
cellular nanovesicles can alter the function of recipient cells. Due to these characteris-
tics, EVs have shown potential as a new alternative for cancer immunotherapy. Tumor 
exosomes isolated from malignant ascites can activate dendritic cells, thereby priming 
the immune system to recognize and kill cancer cells. However, a suppressive role on 
tumor immune response has also been reported, suggesting that the neoplastic stage 
of carcinogenesis and the microenvironment where tumor cells grow may influence the 
amount of EVs released by the cell. This neoplastic stage and microenvironment may 
also impact EVs’ components such as proteins and miRNA, determining their biological 
behavior. Most T-cell lymphomas have an aggressive clinical course and poor prognosis. 
Consequently, complementary alternative therapies are needed to improve the survival 
rates achieved with conventional treatments. In this work, we have characterized EVs 
isolated from ascites of mice bearing a very aggressive murine T-cell lymphoma and 
have studied their immunogenic properties. Small EVs were isolated by differential cen-
trifugation, ultrafiltration, and ultracentrifugation at 100,000 × g on a sucrose cushion. 
The EVs were defined as exosomes by their morphology and size analyzed by electron 
microscopy, their floating density on a sucrose gradient, as well as their expression of 
endosome marker proteins ALIX, TSG-101; the tetraspanins CD63, CD9, and CD81. In 
addition, they contain tumor antigens, the marker for malignancy CD24, the heat shock 
protein HSP-70, and an unusual surface expression of HSP-90 was demonstrated. The 
administration of EVs isolated from ascites (EVs A) into naïve-syngeneic mice induced 
both humoral and cellular immune responses that allowed the rejection of subsequent 
tumor challenges. However, the immunization had no effect on a non-related mam-
mary adenocarcinoma, demonstrating that the immune response elicited was specific 
and also it induced immune memory. In vitro analysis demonstrated that T-cells from 
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inTrODUcTiOn
Extracellular vesicles (EVs) are cell-derived vesicles of dif-
ferent sizes and intracellular origins, including small EVs 
formed inside endosomal compartments and EVs of various 
sizes budding from the plasma membrane (1–3). Exosomes 
are 50–100  nm size EVs, originated from late endosomes, 
which are actively exocytosed to the extracellular medium (2). 
These bioactive nanovesicles, whose function is to promote 
intercellular communication, have been isolated from very 
different cell types including tumor cells. Although the sources 
of exosomes are different, they have common characteristics 
such as the presence of a lipid-bilayer structure containing 
microRNAs, mRNAs, DNA fragments, and proteins. They 
are also similar in size and density. Exosomes express certain 
marker molecules: proteins that designate an endosome origin 
(ALIX, TSG-101) and tetraspanins (CD9, CD63, CD81) (3). 
In addition, others molecules generally found in exosomes are 
heat shock proteins (HSP-60, HSP-70, and HSP-90); proteins 
involved in antigen presentation, e.g., MHC I and MHC II; 
and particularly, exosomes derived from tumors express tumor 
antigens (2, 4).
Direct interaction between tumor cells and their environment 
is essential for cancer progression. To achieve this communica-
tion, effective cross talk is required. Over the last years, it has 
been demonstrated that EVs and exosomes play a critical role 
in cell–cell communication. For example, exosomes are very 
important to induce a pro-carcinogenic microenvironment 
and regulate the immune response aimed at promoting tumor 
progression and survival. To accomplish such survival, exosomes 
remodel the extracellular matrix, inducing angiogenesis, 
thrombosis, and proliferation of tumor cells (5–8). In addition, 
tumor-derived exosomes interact extensively with immune cells 
(9). Exosomes have been demonstrated to activate dendritic cells 
(DCs), thereby priming the immune system to recognize and 
kill cancer cells (4, 9, 10). However, a suppressive role on tumor 
immune response has also been reported. For example, exosomes 
may express Fas-L (11) or galectin (12), which are responsible 
for the induction of apoptosis in activated T-lymphocytes, 
the inhibition of DCs maturation (13), the impairment of the 
lymphocyte response to IL-2 (14), the downregulation of the 
cytolytic activity of NK-cells (15), the generation of regulatory 
T-cells (16), and the blockage of the binding of tumor-specific 
antibodies to tumor cells to reduce antibody-dependent cell 
cytotoxicity reactions (17). Furthermore, the neoplastic stage 
of carcinogenesis and the microenvironment where tumor cells 
grow may influence not only the amount of EVs released but also 
the expression of the molecules in the vesicles and consequently, 
their biological behavior.
The potential of EVs and specially exosomes in the immu-
notherapy of cancer is already being evaluated in clinical trials 
(18, 19). Nevertheless, the contradictory results obtained so far 
in relation to the effectiveness of exosome stimulation on the 
immune system constrain their use. Recent studies have shown 
that exosomes can suppress or induce antigen-specific tolerance 
as well as prime an immune response when injected into naïve 
recipients (20). Despite the vast advances in knowledge of EVs 
and exosomal biology, various issues are not yet fully understood. 
Therefore, to employ exosomes for cancer vaccines, the expres-
sion of different proteins as well as the immune response induced 
by them need to be characterized thoroughly, to ensure that they 
will achieve the desired immunostimulation.
Exosomes derived from B-cell lymphomas already have been 
characterized extensively (21–23); however, there are only a few 
reports describing T-cell lymphoma-derived exosomes. Most 
T-cell lymphomas have an aggressive clinical course and a poor 
prognosis. Consequently, alternative or complementary therapies 
are needed to improve the survival rate already achieved with 
conventional treatments.
In this study, we have characterized the EVs derived from the 
ascites of a very aggressive murine T-cell lymphoma (EVs A) by 
their size, morphology, floating density on a sucrose gradient, 
and the expression of marker-proteins ALIX, TSG-101, CD63, 
CD81, and CD9. In addition, we have investigated their ability to 
modulate tumor-specific immune response by the administration 
of exosomes into syngeneic mice. We have demonstrated that 
EVs A induced both humoral and cellular immune responses. 
The immune response elicited is particularly important in that it 
is specific and induces immune memory; for it failed to reject a 
non-related mammary adenocarcinoma but allowed the rejection 
of subsequent tumor challenges with the same tumor that have 
originated the EVs. Overall, our results demonstrate the ability 
of endosome-derived EVs secreted by an advanced-stage T-cell 
lymphoma, to stimulate an immune specific response.
MaTerials anD MeThODs
cell culture
The syngeneic BALB/c T-cell lymphoma cell line, LBC (H-2d) 
was maintained in RPMI 1640 (Gibco™, Invitrogen, CA, USA) 
supplemented with 10% heat-inactivated, fetal-bovine serum 
(FBS) (Internegocios, Mercedes, Buenos Aires, Argentina), 2mM 
glutamine, 25mM HEPES buffer, 100 IU/ml penicillin, 100 μg/
Keywords: exosomes, T-cell lymphoma, immune response, tumor vaccine, ascites
EVs A-immunized mice secrete IFN-γ in response to tumor stimulation. Furthermore, 
tumor-specific CD4+ and CD8+ IFN-γ secreting cells could be efficiently expanded from 
mice immunized with EVs A, showing that a T helper 1 response is involved in tumor 
rejection. Our findings confirm exosomes as promising defined acellular tumor antigens 
for the development of an antitumor vaccine.
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ml streptomycin, and 0.05 mM 2-mercaptoethanol, as previously 
described (24).
Mice
Six- to ten-week-old female immunocompetent BALB/c 
mice were purchased from the School of Veterinary Sciences, 
Universidad de Buenos Aires (Buenos Aires, Argentina). Animals 
were fed on Cargill pellets and water ad libitum. All animal pro-
cedures were conducted in accordance with Institutional Animal 
Care and Use Committee (CICUAL) guidelines of University of 
Buenos Aires Medical School.
eVs isolation
For the isolation of EVs from ascites (EVs A), BALB/c mice were 
inoculated with 1.0 × 106 LBC cells i.p. At 19 ± 2 days, the mice 
were anesthetized with a combination of ketamine (100  mg/
kg) and xylazina (10 mg/kg) by i.p. injection. The ascitic fluid 
was obtained by ventral puncture. EVs from LBC-cell culture 
(EVs C) were obtained from bovine-EVs-depleted medium 
after 48 h of LBC-cell culture at 37°C and 5% CO2 atmosphere. 
EVs were isolated as previously described (25). Briefly, ascites 
or LBC-conditioned medium were centrifuged at 300 ×  g for 
10  min to separate floating cells. Supernatants were removed 
and centrifuged successively at 800 × g for 30 min, 10,000 × g 
for 30 min. Supernatants were filtered through a 0.22 μm porous 
membrane and centrifuged at 100,000 × g for 1 h on a 30% sucrose 
weight/volume (w/v) cushion. EVs contained in the 30% sucrose 
cushion were resuspended in phosphate-buffered saline (PBS) 
and were concentrated in a last step of 1 h ultracentrifugation 
at 100,000 × g.
The EVs in the pellet were resuspended in PBS and kept at 
−80°C. The amount of exosomal proteins recovered was deter-
mined by the Bradford method (25).
cell lysates
Protein LBC-Cell Lysates (LBC p-Lysate)
Protein LBC-cell lysates (LBC p-lysate) were obtained by incu-
bating cell suspensions with a lysis buffer for 20 min on ice and 
centrifuged as previously described (25).
Freeze–Thaw Lysates (LBC Lysate)
LBC cells were harvested and washed twice with PBS. Cells were 
then suspended in PBS (2.0 × 106 cells/ml) and lysed by means 
of three to four cycles of freezing at −70°C and thawing at 37°C, 
vortexing after each round. Total cell death was confirmed by 
trypan blue dye exclusion. Protein concentration was determined 
by the Bradford method. Lysates were then aliquoted and stored 
at −70°C until used.
cell immunofluorescence staining and 
Flow cytometry
LBC-cell staining was performed as previously described (24). 
The following antibodies were employed: anti-mouse CD-24-PE, 
anti-CD8-PE MAbs, and isotype-matched controls (eBiosci-
ence, CA, USA). After incubation with anti-MHC I-Biotin 
primary antibody, the cells were washed and then incubated with 
streptavidin–phycoerythrin (PE) conjugated (eBioscience, CA, 
USA). Fluorescence was measured in a BD FACSCalibur flow 
cytometer (BD Biosciences, San Jose, CA, USA). The data were 
analyzed with the Flowing 2.5.1 software.
eVs immunofluorescence staining and 
Flow cytometry
Five micrograms of EVs A were incubated with 4-μm diameter 
aldehyde/sulfate latex beads (Invitrogen, CA, USA), as detailed in 
Ref. (25, 26). Bound EVs were spun down, and the unoccupied 
sites were saturated with 100 mM glycine. Then, the EVs were 
incubated with anti-mouse CD24-PE, anti-CD8-PE, and isotype-
matched controls (eBioscience, CA, USA). After incubation with 
anti-MHC I-Biotin, CD9-Biotin, CD81-Biotin (eBioscience, CA, 
USA), anti-HSP-70, and anti-HSP-90 (Santa Cruz Biotechnology, 
TX, USA) primary antibodies, the EVs-coated beads were incu-
bated with a streptavidin–PE-conjugated (Invitrogen, CA, USA) 
or an Alexa647-conjugated secondary antibody, respectively 
(Jackson Immuno Research, PA, USA). Fluorescence was meas-
ured in a BD FACSCalibur flow cytometer (BD Biosciences, CA, 
USA). The data were analyzed with the Flowing 2.5.1 software.
electron Microscopy
To visualize the EVs’ preparations by electron microscopy, EVs 
were fixed with 4% paraformaldehyde and loaded into electron 
microscopy grids (25). Samples were then observed in a trans-
mission electron microscope Phillips Tecnai-10. Vesicles size was 
assessed with analysis ImageJ analysis software.
sucrose gradient
The floatation of EVs released by LBC cells was performed in 
a continuous sucrose gradient as described for exosomes (25). 
Gradient fractions (0.2 ml each) were diluted in 4 ml PBS, cen-
trifuged for 1 h at 100,000 × g, resuspended in Laemmli sample 
buffer, separated on a 10% SDS-PAGE, and transferred onto a 
nitrocellulose membrane (Hybond-ECL nitrocellulose mem-
brane, 0.2-μm transfer membrane; GE Amersham Life Sciences, 
USA). Specific proteins then were detected as explained for 
western blot.
sDs-Page and Western Blot
Ten micrograms of EVs or cell lysates were resuspended in 
Laemmli sample buffer and separated by electrophoresis on 10% 
SDS-polyacrylamide gels. Gels were electroblotted onto nitrocel-
lulose paper (Hybond-ECL nitrocellulose membrane, 0.2-μm 
transfer membrane; GE Amersham Life Sciences, USA) and 
blocked overnight with 5% non-fat dry milk in Tris buffer saline 
(B-TBS). Blots were incubated overnight at 4°C with mouse anti-
CD63, anti-TSG-101, anti-ALIX, anti-HSP-70, or anti-HSP-90 
antibodies (Santa Cruz Biotechnology, TX, USA). Finally, blots 
were washed and incubated with an anti-mouse HRP-conjugated 
or an anti-rabbit HRP-conjugated serum. Membranes were 
revealed with the ECL kit (GE, Amersham Life Sciences, USA) 
following the manufacturer’s instructions. The GE Healthcare, 
Image Quant TM-RT ECL, Version 1.0 software was used to 
detect specific proteins (25).
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Dot Blot
One mircoliter of LBC EVs, or LBC-cell lysate samples, or 2 μl 
of LBC-cell samples containing 1 μg of EVs or cell lysates and 
10,000 LBC cells, respectively, were spotted onto a nitrocel-
lulose membrane (Hybond-ECL nitrocellulose membrane, 
0.2-μm transfer membrane; GE Amersham Life Sciences, 
USA). Membranes were blocked and incubated overnight at 
4°C using different dilutions (from 1:200 to 1:6,400) of sera 
from naïve mice or from mice immunized LBC-cell lysate. Blots 
were washed and incubated with anti-mouse HRP-conjugated 
sera for 1  h. Specific proteins were detected as explained for 
western blot.
Mice immunization and Tumor challenge
Mice were randomly divided into groups and vaccinated i.p. 
once a week for 2 weeks. For each injection, each group of mice 
received 10 μg EVs A/ml/mouse, EVs C, or PBS alone as control. 
Seven days after the last immunization, animals were challenged 
with 1.0 × 106 LBC tumor cells i.p., which is a dose that has been 
determined to cause 100% lethality 21 ± 4 days after injection. 
Mice survival was monitored daily, and the mortality rate and 
survival were recorded (27).
To evaluate whether mice developed a memory response, mice 
vaccinated with EVs A, EVs C, or LBC lysate that had rejected the 
first tumor challenge were rechallenged with 1.0 × 106 LBC tumor 
cells i.p. 30 days after the first tumor injection. The survival time 
of animals was recorded daily. Survival curves from these treated 
mice were compared with survival curves from the naïve-age-
matched mice that had been inoculated i.p. with 1.0 × 106 LBC 
cells at the same time.
To assess the specificity of the immune response generated, 
EVs A or EVs C-immunized mice that had rejected the LBC 
tumor and naïve mice were inoculated with 2.0  ×  105 LM3 
mammary adenocarcinoma cells subcutaneously into the right 
flank (28). The mice developed a palpable, solid tumor in the 
inoculated region tumor on day 11 postinoculation. The animals 
were sacrificed when the tumor reached a volume of 1  cm3, 
approximately 40 days postinoculation.
carboxyfluorescein succinimidyl ester 
(cFse) Proliferation assay
BALB/c mice were immunized with LBC-cell lysate once a 
week for 2 weeks. On day 14, spleen cells were obtained under 
sterile conditions. The proliferative behavior of the lymphocytes 
was quantified by the CFSE dilution. The CFSE staining was 
performed before seeding, using the CFSE (Invitrogen, CA, 
USA) at a final concentration of 5  μM for 10  min at room 
temperature, followed by immediate quenching with culture 
medium. CFSE stained splenocytes (1.0 × 106/ml) were seeded 
in a 24-well plate and incubated during 5  days with 10 μg of 
EVs, alone; 10 μg of LBC lysate, alone; and 10 μg of EVs A and 
1 μg of concanavalin A (CON A), together in the same well. For 
the positive and negative controls splenocytes were incubated 
with 1 μg of CON A and RPMI complete medium, respectively. 
To analyze T-cell subpopulations, stimulated and CFSE stained 
splenocytes were incubated with PE-conjugated anti-CD8 or 
anti-CD4 monoclonal antibodies. In vitro stimulated splenocytes 
were analyzed by flow cytometry. Fluorescence was measured in 
a BD FACSCalibur flow cytometer (BD Biosciences, CA, USA). 
The data analysis was performed with the Flowing 2.5.1 software 
(29). Relative proliferative index (RPI) is defined as the ratio 
between the percentages of stimulated cells by the percentage 
of control cells.
intracellular staining for iFn-γ
Spleens cells were obtained from naïve mice or immunized with 
EVs A once a week for 2 weeks. Splenocytes (1.0 × 106/well) were 
seeded in a 96-well plate. After stimulation with 10 μg of EVs A 
or 10 μg of LBC lysate during 48 h, splenocytes were incubated 
with Golgi Stop® (Monensin, BD Biosciences, CA, USA), accord-
ing with manufacturer’s recommendations, for the final 6  h, 
and centrifuged at 250 ×  g for 5  min. Cells were resuspended 
in staining buffer (PBS supplemented with 0.1% sodium azide 
and 5% FBS, pH 7.4–7.6), and the intracellular staining for 
IFN-γ expression was accomplished as previously detailed (30). 
Double-color surface staining was first performed with fluores-
cein isothiocyanate-conjugated anti-CD4 and PE-conjugated 
anti-CD8 monoclonal antibodies, and then cells were fixed with 
4% paraformaldehyde and permeabilized with permeabilization 
buffer (PBS supplemented with 0.1% sodium azide, 1% FBS, 
and 0.1% saponin) and stained with an allophycocyanin-labeled 
anti-IFN-γ mAb (eBioscience, USA). Samples were acquired in 
a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, 
USA). Lymphocytes were initially gated by forward scatter/
side scatter; secondary gates were set on the basis of staining 
with isotypic control monoclonal antibodies so that fewer than 
1% of cells stained positive. Multiple control experiments were 
performed to validate the applicability of intracellular staining 
for cytokines, according to previously reported methods (29). 
Accordingly; we stained unstimulated splenocytes from naïve and 
immunized mice and lymphocytes that had been cultured for 6 h, 
with phorbol-12-myristate-13-acetate (PMA, ICN Biomedicals, 
CA, USA) at 50 ng/ml and calcium ionophore ionomycin (ICN 
Biomedicals, CA, USA) at 1 μM.
cytokine Measurements
Briefly, splenocytes obtained from naïve or EVs A-immunized 
mice were seeded at a concentration of 1.0 × 106 cells per well 
in 96-well plates and incubated for 48  h at 37°C. IFN-γ levels 
were measured in culture supernatants by enzyme-linked immu-
nosorbent assays (ELISA) using a commercial kit (eBioscience) 
following the manufacturer’s instructions. Samples were read at 
492 nm (31).
statistical analysis
The survival fractions were calculated using the product-limit 
Kaplan–Meier method, and differences between treatments 
were evaluated by log-rank statistic. For statistical comparisons, 
a one-way ANOVA with Tukey’s posttest was used. Differences 
were considered significant at p values <0.05 for all compari-
sons. The statistical analysis was performed using GraphPad 
Prism software 5.1 for Windows (GraphPad Software, San 
Diego, CA, USA).
FigUre 1 | (a) Electron microscopy of purified extracellular vesicles (EVs) 
isolated from ascitic fluid samples, demonstrating the typical shape and size 
(60–110 nm) of exosomes, and graphic of the size-distribution of the 
vesicles measured with ImageJ software of at least eight micro-photos. 
(B) Characterization of EVs isolated by sucrose density gradient. The 
sample was loaded on top of a step sucrose gradient, and six fractions 
were collected and analyzed for exosomal proteins. Aliquots of fractions 
collected from the top of the gradient were analyzed by dot blot for 
TSG-101 and western blotting with antibodies against HSP-70 and 
TSG-101. M = pellet from 100,000 × g ultracentrifugation not submitted to 
a sucrose gradient sedimentation.
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resUlTs
isolation of eVs Derived from ascites 
of Mice Bearing lBc lymphoma
LBC lymphoma is an aggressive tumor. The terminal phase 
of the disease occurs between days 17 and 21 post-challenge 
(24). At 19 ± 2 days, when mice developed tumor ascites that 
were visually detectable, ascitic fluid was obtained, and the 
EVs were isolated. The average concentration of tumor cells in 
the ascitic fluid was 1.70 × 108 ± 0.50 × 108 cells/ml, and the 
average of EVs isolated, assessed as protein concentration, was 
0.72 ± 0.06 μg/1.0 × 106 LBC cells.
Morphological characterization and 
Protein Profile of eVs a
Ascitic fluid contains several types of EVs; therefore, we per-
formed a characterization of the EVs obtained according to their 
morphological and physical properties as well as their protein 
profile. The morphological characteristics were analyzed by 
electron microscopy. As shown in Figure 1A, the EVs were not 
homogeneous, displaying the characteristic morphology and size 
(50–100 nm) of exosomal samples.
The density is another parameter widely used to charac-
terize EVs (32, 33). It is well known that exosomes float on 
a continuous sucrose density gradient ranging from 1.15 to 
1.19  g/ml. To characterize the nanovesicles obtained from 
the ascites, the vesicles were analyzed by their flotation in 
a continuous sucrose density gradient. After centrifugation, 
the density gradient fractions were analyzed by dot blot and 
western blot using a monoclonal antibody specific for the 
TSG-101 protein, which is a protein expressed by exosomes 
and associated with the endosomal origin of the nanovesicles. 
As seen in Figure 1B, the presence of EVs derived from ascites 
located at densities 1.1222, 1.1513, 1.1663, and 1.1868  g/ml 
was reveled by the expression of the TSG-101, analyzed by 
dot blot. Similar results were obtained by analyzing samples by 
western blot (Figure 1B). The lanes corresponding to fractions 
2 and 3 (1.1513 and 1.1663 g/ml, respectively) revealed a band 
corresponding to TSG-101 (44  kDa) and lanes 2, 3, and 4 to 
HSP-70 (70  kDa), which is also a protein usually found in 
exosomes.
To characterize the isolated nanovesicles, the protein profile 
of the tetraspanins classically used as exosomes markers, CD63, 
CD9, and CD81 and the endosome-associated proteins ALIX 
and TSG-101, were studied by flow cytometry and western blot 
(Figures 2A,B). By flow cytometry, it was demonstrated that 94% 
of EVs A express CD63 and almost 90% were TSG-101 positive; 
while 91 and 88% of the EVs A express the tetraspanins CD81 
and CD9, respectively. These results were confirmed by western 
blot and in addition, the presence of ALIX and TSG-101 were 
demonstrated (Figure 2B).
Heat shock proteins are proteins commonly expressed 
in exosomes, and their localization may determine their 
immunological properties. Thus, one of the objectives was to 
analyze the localization of these proteins in EVs A. We first 
demonstrated that both HSP-90 and HSP-70 are expressed 
EVs A by western blot (Figure  2B). To further investigate the 
location of HSP on the outer surface of EVs A, we coupled 
EVs A to aldehyde–sulfate latex beads, and the expression of 
HSP-70 and HSP-90 was analyzed by flow cytometry. As shown 
in Figure  2A, HSP-90 was highly expressed on the surface of 
EVs A, while HSP-70 could not be revealed on EVs A by flow 
cytometry. HSP-70 expression could only be demonstrated by 
western blot (Figures 2A,B). Taken together, the results obtained 
by flow cytometry and western blot suggest that HSP-70 lies 
encapsulated in the exosomal lumen, and that HSP-90 is present 
on the surface. However, the presence of HSP-90 also in the 
EVs’ lumen cannot be ruled out.
Due to their importance in the antitumor immune response, 
we next focused on those proteins with immunological relevance 
expressed on EVs A and compared them with the cells from 
which they derive (LBC ascites). Furthermore, we also included 
in the study LBC cells from in  vitro-cultured-cell line  and the 
EVs isolated from their conditioned medium (EVs C). By flow 
cytometry, we demonstrated that EVs A express proteins 
involved in antigen presentation such as MHC I, CD8, and 
the heat stable antigen CD24 (Figure  3A). As shown in the 
Figure 3A, LBC cells either growing in vitro or in vivo as well 
as EVs secreted by them, expressed similar levels of CD8, MHC 
I, and CD24. CD24 is a molecule expressed on thymocytes 
but not on mature thymic and peripheral T-cells and indicates 
FigUre 2 | (a) Flow cytometry detection of surface molecules on extracellular vesicles (EVs). EVs were incubated with aldehyde–sulfate latex beads and stained 
with monoclonal antibodies or specific isotype-matched control antibodies. Analysis was performed on singlet gate of a forward scatter versus side scatter dot plot. 
Filled histograms represent exosome–bead complexes stained with specific monoclonal antibodies, the unfilled histogram represents isotype control antibodies. 
(B) Immunoblot protein analyses of EVs. EVs A (EVs isolated from ascites) and the LBC-cell lysate (LBC p-Lysate) were separated on a SDS-PAGE and electroblotted 
onto a nitrocellulose membrane. Samples were incubated with antibodies specific for heat shock proteins (HSP-70 and HSP-90) and specific markers for exosome 
as ALIX, TSG-101, and CD63.
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FigUre 3 | Flow cytometry analysis of extracellular vesicles (eVs) and lBc cells. (a) Samples were incubated with antibodies specific for CD24, CD8, and 
MHC I. Analysis was performed on singlet gate of a forward scatter versus side scatter dot plot. Filled histograms represent LBC cells stained with specific 
monoclonal antibodies, the unfilled histograms represent EVs–bead complexes, and dot line represents irrelevant-isotype-control antibodies. Graphs correspond to 
one representative of four independent experiments. EVs C, EVs isolated from LBC cell line. (B) Dot blot characterization of tumor-associated antigens in EVs A and 
LBC cells. Dot blot analysis of 1 μg LBC-cell lysates, 10,000 LBC cells (LBC), and 1 μg of LBC EVs. EVs proteins and LBC lysates proteins were separated on a 
SDS-PAGE and electroblotted to nitrocellulose. Blots were probed with sera from naïve (NS) or LBC lysate-immunized (LBC-IS) mice.
7
Menay et al. Exosomes Isolated from Ascites of T-Cell Lymphoma
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 286
8Menay et al. Exosomes Isolated from Ascites of T-Cell Lymphoma
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 286
the degree of malignancy in several tumors. CD24 is highly 
expressed on LBC as these cells are derived from an early T-cell 
precursor. The fact that more than 90% of EVs, either derived 
from ascites or from conditioned medium of LBC cells, express 
CD8 and CD24 suggests the tumor origin of the EVs A.
Based on our results, the small size of the EVs isolated and 
the expression of ALIX and TSG-101 together with the presence 
of CD63, CD9, and CD81 are strong evidence that the isolated 
nanovesicles are exosomes. Furthermore, we demonstrated that 
the amount of CD24 in EVs A correlated with the amount of 
CD8 and therefore most of the CD24-positive EVs are secreted 
by LBC cells.
eVs a express Tumor-associated antigens
Previous studies have shown a common protein pattern between 
exosomes derived from different cell types and proteins present 
exclusively in tumor-derived exosomes. We next investigated 
the existence of common antigens between LBC tumor cells 
and EVs A. LBC cells and EVs A were analyzed by dot blot, 
then probed with sera obtained from naïve mice (normal sera, 
NS) and mice immunized with LBC-cell lysate (immune sera, 
LBC-IS), as detailed in Section “Materials and Methods.” Upon 
incubating LBC cells and exosomes with IS, a high signal for LBC 
cells and exosomes was observed, obtaining titers of up to 1:6400 
(Figure 3B). However, no signal was obtained when EVs A and 
LBC cells were incubated with NS. These results allow inferring 
that specific antibodies against LBC present in serum obtained 
from immunized mice do, in fact, recognize antigens on EVs A 
in a similar way. Therefore, it could be speculated that EVs A and 
tumor LBC cells share tumor antigens.
eVs a stimulate specific splenocytes 
In Vitro
Extracellular vesicles from tumor cells have proved either to 
suppress or to activate the immune response. Since EVs A were 
isolated from the ascites of mice in the terminal stage of the 
tumor development, where the immunosuppressive properties 
limiting the immune system’s ability to restrain the tumor may 
be present, we initiated the study by determining the effect of 
exosomes over the lymphocyte proliferative rate. Splenocytes 
obtained from mice immunized with LBC lysate as well as naïve 
mice were stained with CFSE, stimulated with CON A and 
cocultured with EVs A.
The maximum proliferative rate was reached with CON-A-
stimulated splenocytes regardless of whether or not they were 
incubated with EVs A. As shown in Figure 4A, when lymphocytes 
were stimulated with CON A and cultured with EVs A, 93% of 
lymphocytes displayed a left shift indicating a dilution of CFSE 
due to the proliferative response. Similar results were obtained 
when the cells were incubated only with CON A demonstrating 
that EVs A does not suppress the CON A-driven lymphocyte 
proliferation.
In a parallel experiment, the stimulatory capacity of EVs A was 
evaluated. Spleen cells obtained from mice previously immunized 
with LBC lysate and labeled with CFSE were cultured with EVs A 
or LBC lysate, used as a positive control. As shown in Figure 4B, 
after 5 days of culture, both EVs A and LBC lysate had similar, 
potent stimulatory capacities. The RPI was 11.54 ±  1.21 and 
12.78 ± 1.39 for LBC-cell lysate and EVs A, respectively. A sig-
nificant difference (p < 0.001) was observed for both treatments, 
when comparing each group with the unstimulated control 
(RPI = 1). In additional experiments, we studied the proliferation 
induced by the EVs A on CD4+ and CD8+ T-cells. As shown 
in Figure 4C, EVs A promote a specific proliferation of CD4+ 
lymphocytes (15%) and a slight proliferation of CD8+ (3%) when 
compared with non-stimulated splenocytes.
To further investigate the immune response induced by EVs 
A, the levels of IFN-γ were determined in culture supernatants 
of splenocytes obtained from LBC lysate-immunized mice, as an 
indication of a T helper 1 (Th1) response. EVs A induced the 
production of IFN-γ by splenocytes derived from immunized 
mice (Figure 5). Furthermore, the levels of IFN-γ were similar 
when splenocytes were stimulated with either EVs A or the 
LBC-cell lysate when compared with unstimulated splenocytes 
(p < 0.001).
eVs a Vaccination induce Protection 
against Tumor challenge
To test the potential immunogenicity of EVs A in vivo, we ana-
lyzed the effects of a previous immunization with two doses of 
EVs A on the outcome of a subsequent challenge with live tumor 
cells. To this end, groups of BALB/c mice were prophylactically 
immunized on days −14 and −7 with 10 μg of EVs A, EVs C, with 
LBC lysate or with PBS, as positive or negative controls, respec-
tively. To evaluate the immune response elicited, at day −1, serum 
samples from immunized mice were obtained and evaluated by 
dot blot for the presence of specific antibodies. On day 0, mice 
were challenged by an i.p. administration of LBC viable cells and 
the survival was recorded.
As shown in Figure  6A, the immunization with EVs A 
induced specific antibodies against both LBC tumor cells and EVs 
A. The antibody titer was slightly higher for EVs A than for LBC 
cells, while no specific antibodies were found in naïve mice sera 
(inoculated with PBS).
Approximately 60% of mice immunized with the EVs and chal-
lenged with LBC cells did not develop the tumor. Similar results 
were observed for mice vaccinated with LBC lysate; whereas all 
age-matched control mice developed tumors and died by day 22 
post-challenge. Similar results were obtained immunizing mice 
with 10 μg of EVs isolated from LBC cells conditioned medium 
(EVs C) (Figure 6B).
To assess whether the immunization with EVs A could induce 
a long-term antitumor immunity against a second parent tumor 
challenge, mice that had survived over 30 days after tumor cell 
injection and naïve mice, used as control, were reinoculated 
with LBC cells i.p. All mice immunized with EVs A, EVs C, and 
the LBC lysate survived the lethal tumor rechallenge for more 
than 120 days, whereas 100% of mice in the control group died 
(Figure 6C).
To determine whether the immune response triggered by 
EVs A was tumor specific, mice surviving the first-LBC tumor 
challenge were rechallenged with the mammary adenocarcinoma 
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FigUre 4 | continued
FigUre 5 | iFn-γ production. Spleen cells obtained from mice previously 
immunized with LBC lysate were incubated for 5 days at 37°C. Supernatants 
were then collected and IFN-γ levels were measured in culture supernatants 
by enzyme-linked immunosorbent assays. Error bars indicate SD of duplicate 
samples from a representative of two independent experiments. Asterisks 
indicate significant differences (***p < 0.001).
FigUre 4 | continued 
evaluation of the immune properties of eVs a in vitro. (a) Immunosuppressive capacity of EVs A. Splenocytes obtained from naïve mice were stained with 
carboxyfluorescein succinimidyl ester (CFSE) and incubated with 1 μg of concanavalin A (CON A) or 1 μg CON A + 10 μg EXO A in RPMI plus 5% fetal-bovine 
serum for 5 day. (B) Stimulatory capacity of EVs A. Splenocytes obtained from mice sensitized in vivo with LBC lysate were labeled with 5 μM CFSE and cultured for 
5 days with 10 μg EVs A or 10 μg of LBC lysate (green-filled histogram). Flow cytometry histograms corresponding to non-stimulated splenocytes stained with 
CFSE used as negative control (green line histogram), unstained non-stimulated splenocytes (black line histogram). RPI, relative proliferative index, is defined as the 
ratio between the percentages of stimulated cells by the percentage of control cells. The percentage of proliferating cells was taken from G0 (not included) to the 
beginning of autofluorescence. The numbers in the graph correspond to the percentage of the gated region: R2, unstimulated CFSE stained cells; R1, 
autofluorescence; and R3, proliferating cells. Graphs correspond to one representative of two independent experiments. (c) Proliferation of CD4+ and CD8+ 
lymphocytes. Splenocytes obtained from mice sensitized in vivo with LBC lysate were labeled with 5 μM CFSE and cultured for 5 days with 10 μg EVs A or 0.5 μg 
CON A. Flow cytometry histograms corresponding to non-stimulated splenocytes stained with CFSE used as negative control (green line histogram), unstained 
non-stimulated splenocytes (black line histogram). The percentage of proliferating cells was taken from G0 (not included) to the beginning of autofluorescence. 
Graphs correspond to one representative of two independent experiments. Lymphocyte gate was determined by forward and side scatter. CFSE dye dilution was 
analyzed gating on CD4 and CD8 cell fractions.
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LM3. As a positive control, naïve mice were inoculated with 
the LM3 tumor. All mice (those immunized with EVs A, EVs 
C, or LBC-cell lysate as well as the control animals) developed 
a palpable tumor on day 11 postinoculation. On day 40, when 
mice reached the final stage of tumor disease, all were sacrificed 
(data not shown).
immunization of BalB/c Mice with eVs a 
generate iFnγ-Producing cD4+ and cD8+ 
cells
To elucidate whether the immunization elicited a Th1 response, 
35 days after tumor challenge we determined the levels of IFN-γ 
in splenocytes supernatant obtained from immunized mice and 
cocultured during 48  h either with EVs A or the LBC tumor 
lysate. This period was selected since the average death time for 
control animals (age-matched naïve) was 22 days.
Figure 7A displays the levels of IFN-γ in the supernatant of 
splenocytes obtained from immunized mice cocultured during 
48 h either with EVs A, the LBC-cell lysate, or medium alone. 
High levels of IFN-γ were detected in supernatants of splenocytes 
from immunized animals stimulated with either EVs A or the 
LBC lysate, as compared to unstimulated (EVs A p < 0.01 and 
LBC lysate p < 0.05) cells or those obtained from naïve mice (EVs 
A p < 0.001 and LBC lysate p < 0.05), suggesting the induction 
of a Th1 response.
To further characterize the cellular immune response induced, 
the intracellular IFN-γ staining was performed for specific T-cells 
subsets (Figure 7B). While naïve mice did not generate a LBC-
specific T-cell response, mice immunized either with EVs A or 
the LBC lysate showed a significant increase of IFN-γ-producing 
CD4+ and CD8+ T-cells, when compared with those cells 
obtained from naïve mice (EVs A CD4+ p <  0.01; LBC lysate 
CD4+ p < 0.05 and EVs A CD8+ p < 0.01; LBC lysate CD8+ 
p < 0.05). An approximate twofold and onefold increase in IFN-
γ-secreting CD4+ T-cells were induced when splenocytes from 
immunized mice were stimulated with EVs A and LBC lysate, 
respectively, compared with CD4−IFN-γ+ cells from naïve-
control mice. Whereas an approximate 1- and 0.25-fold increase 
in IFN-γ-secreting CD8+ T-cells was found for EVs A and 
LBC lysate stimulated splenocytes, respectively, in immunized 
mice compared with CD8−IFN-γ+ from naïve-control mice 
(Figure 7C).
DiscUssiOn
In this paper, we characterized EVs isolated from ascites of tumor-
bearing mice in the late stage of the neoplastic development, and 
we gave an insight into the understanding of the relationship 
between tumor-associated antigens, immune relevant molecules, 
and their immune stimulating properties.
Ascites contain various types of cells and EVs; therefore, 
it was essential to confirm that the samples obtained were 
indeed exosomes (2). Our results demonstrated that LBC cells 
contained in ascites of tumor-bearing mice release EVs with 
biochemical and morphological characteristics that are those 
corresponding to exosomes. In fact, such EVs were found to 
express the exosomal-hallmarks CD9, CD81, CD63, and the 
endosomal sorting required for transport proteins, TSG-101 and 
ALIX. Besides, these EVs had a size and morphology and had 
the buoyant density in sucrose gradients reported for classical 
exosomes (2–4, 32).
FigUre 6 | Protective immune response against lBc tumor induced 
by eVs a immunization. (a) Serum-specific antibodies against LBC cells. 
One microgram of exosomes or 10,000 LBC cells were spotted onto a 
nitrocellulose membrane. Membranes were blocked and incubated 
overnight at 4°C with different dilutions (from 1:1,600 to 1:12,800) of sera 
from naïve mice (NS) or from mice immunized with LBC lysate (LBC-IS). 
(B) Survival curves of mice immunized with EVs A. Immunocompetent naïve 
BALB/c mice were inoculated i.p. twice with 10 μg/mouse of EVs A with an 
interval of 7 days or with LBC lysate or EVs C. Seven days after the last 
immunization, mice were challenged with 1.0 × 106 LBC tumor cells i.p. 
Phosphate-buffered saline (PBS) corresponds to the non-immunized control 
group, inoculated with PBS and challenged with the LBC tumor cells. 
N = 12/group. Graphs correspond to one representative of two independent 
experiments. (c) Survival curves of mice after tumor rechallenge. Mice 
vaccinated with EVs A or LBC lysate that had rejected the first tumor 
challenge were rechallenged with 1 × 106 LBC tumor cells i.p. 30 days after 
the first tumor injection. N = 6/group. The curves corresponding to EVs A, 
EVs C, and LBC lysate overlap.
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Lambrecht et  al. have demonstrated that exosomes purified 
from malignant effusions of patients with breast, ovarian, or 
lung cancer may be released not only by tumor cells but also by 
dendritic, B, and T-cells (34). The expression of CD24 and CD8 
in 90% of EVs A excluded the presence of EVs from other cells 
such as dendritic, B, and T-cells present in malignant effusions 
of the peritoneum cavity (Supplementary Figure S1). Indeed, 
CD24 is expressed in a variety of malignancies including B-cell 
lymphoma, renal-cell carcinoma, nasopharyngeal carcinoma, 
hepatocellular carcinoma, bladder carcinoma, glioma, ovarian, 
and breast cancer. The expression of CD24 on LBC lymphoma 
correlates with the early stage of T-cell differentiation when the 
neoplastic transformation of the tumor cells took place (24). 
The high-level expression of CD24 has been correlated with the 
degree of tumor progression. Accordingly, CD24 is used as a cel-
lular marker of progression for this lymphoma (24) as it is used 
for other tumors (35) associated with poor prognosis.
When analyzing the expression of HSP-70 and HSP-90, 
proteins also enclosed in EVs that are very well known for their 
adjuvant activity on immune responses, a different distribution of 
these proteins was observed when compared to LBC cells. While 
these proteins were expressed intracytoplasmatically in LBC cells 
(Supplementary Figure S2), a translocation to the surface of EVs 
A occurred for HSP-90. Indeed, this protein is normally found 
intra-lumen in exosomes (36, 37). Accordingly, we demonstrated 
an elevated expression of HSP-90 on the surface of EVs A, but 
not on the surface of EVs derived from the thymoma EL4 cells 
(Supplementary Figure S2). The surface expression of HSP-90 
on LBC EVs may allow their binding to DCs-surface receptors 
such as CD91, inducing cell maturation. This atypical cell-surface 
expression of HSP-90 may also contribute to a tumor-specific cel-
lular immunity, as demonstrated for mast cell-derived exosomes 
(38). Even more remarkable, Spisek et al. have demonstrated that 
the induction of HSP-90 on the surface of human myeloma cells 
enhances the uptake of tumor antigens by DCs, leading to the 
induction of antitumor immunity (39).
Additionally, EVs A express immunologically relevant 
molecules on the surface such as CD8 MHC class I and LBC 
tumor-specific antigens. These antigens present on EVs A are 
recognized in  vitro by memory lymphocytes generated in  vivo 
with LBC lysate. In fact, we have demonstrated by means of 
lymphocyte proliferation assay that LBC exosomes are stimula-
tors of the immune system, inducing a potent Th1 response with 
tumor-specific CD4 and CD8 expansion and the production of 
IFN-γ. Even more, LBC EVs exert an in vivo immune stimulation 
that is both cellular and humoral. The immunization with LBC 
EVs induced an immune response featured by specific IFN-γ 
CD4+ and CD8+ secreting T-cells and the synthesis of antibodies 
against LBC cells.
Contrary to the findings for other exosomes present in malig-
nant effusions with suppressors properties (40, 41), EVs released 
by this T-cell lymphoma induced a potent immune response and 
could be use as acellular antigens. In fact, we demonstrated that 
EVs A induced a significantly high immune response since it 
allowed mice post-challenge survival. Moreover, the immuni-
zation with EVs A conferred a long-lasting memory response, 
since it induced protection against a second challenge with the 
LBC tumor.
The advantage of employing EVs and exosomes for cancer 
immunotherapy lies in the use of acellular tumor-associated 
antigens that are indistinguishable from those expressed on the 
cell from which they derive. Besides, this stimulation would 
increase efficiency, since tumor antigens are concentrated in EVs. 
Moreover, they are highly reproducible, easy to store, safer, and 
more stable than irradiated cells.
Our results revalue the use of nanovesicles as acellular anti-
gens to be used in immunotherapy against cancer. It is of great 
FigUre 7 | continued
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FigUre 7 | continued 
immune response induced in eVs a-immunized mice. (a) IFN-γ levels in the supernatant of splenocytes from mice immunized with EVs. Spleen cells obtained 
from naïve mice or mice previously immunized with EVs A were incubated for 48 h at 37°C. Supernatants were then collected, and IFN-γ levels were measured in 
culture supernatants by enzyme-linked immunosorbent assays. Error bars indicate SD of duplicate replicates from a representative of two independent experiments. 
Asterisks indicate significant differences (*p < 0.05, **p < 0.01, and ***p < 0.001). (B) Intracellular staining for IFN-γ in lymphocytes from mice immunized with EVs 
A. Spleen cells obtained from naïve or mice previously immunized with EVs A were incubated for 48 h at 37°C. Double-color surface staining was first performed 
with conjugated mAbs fluorescein isothiocyanate -anti-CD4 and PE-anti-CD8, and then cells were permeabilized with saponin and stained with allophycocyanin-
anti-IFN-γ. To analyze intracellular cytokine expression by CD4+ and CD8+ lymphocytes, a gate was first drawn around the lymphocytes in a dot plot of forward 
scatter versus SSC. A second gate was drawn around the CD4+ or CD8+ lymphocytes in the CD4 versus CD8 dot plot. Non-stimulated splenocytes were used as 
negative control (RPMI). Splenocytes cultured 6 h with PMA at 50 ng/ml and ionomycin at 1 μM were used and as positive control (data not shown). (c) Average 
fold increase in IFN-γ-producing cells. This index is defined as the ratio between % stimulated IFN-γ-producing cells and % IFN-γ-producing cells of unstimulated 
splenocytes. The % IFN-γ-producing cells used for the calculation was previously subtracted by the % of unstimulated control. Error bars indicate SD of duplicate 
samples from a representative of two independent experiments. Asterisks indicate significant differences (*p < 0.05, **p < 0.01, and ***p < 0.001). N = 6/group.
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importance to define the molecular composition of the EVs and 
exosomes together with its immunomodulatory properties for 
each tumor, prior to its use as therapy, because nanovesicles have 
the ability to activate or inhibit the immune system. EVs therapy 
offers a promising alternative to a better immune strategy for the 
development of cancer vaccines.
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